2015 Aug 25;8:372. doi: 10.1186/s13104-015-1344-0.Pediatr Res. Siklos ® can lessen the frequency of pain for your child with sickle cell disease Children with sickle cell disease experience “painful crises” when their sickle-shaped red blood cells block their blood vessels, preventing blood and oxygen from reaching their tissues and causing pain. Incomplete Awareness or Knowledge about Hydroxyurea (HU) among Parents Detailed Hydroxyurea dosage information for adults and children. Sickle cell disease (SCD) is an inherited disorder in which sickled red blood cells occlude the small vessels of the body, reducing oxygen delivery to tissues and ultimately negatively affecting many of the body’s major organs. Reversible cytopenias occurred in 22% of patients, primarily neutropenia and thrombocytopenia. Recent NHLBI evidence-based guidelines highlight this as a critical knowledge gap, noting HbSC accounts for ∼30% of sickle cell patients within the United States. This site needs JavaScript to work properly. 2001 Jun-Jul;23(5):306-8. doi: 10.1097/00043426-200106000-00014.Creary SE, Modi AC, Stanek JR, Chisolm DJ, O'Brien SH, Nwankwo C, Crosby LE.J Pediatr Psychol. Epub 2014 Apr 17.Segal JB, Strouse JJ, Beach MC, Haywood C, Witkop C, Park H, Wilson RF, Bass EB, Lanzkron S.Evid Rep Technol Assess (Full Rep). 2020 Jul 14;9(7):e16319. Wiley 2014 Sep;61(9):1536-9. doi: 10.1002/pbc.25073. Epub 2018 Mar 17. COVID-19 is an emerging, rapidly evolving situation. 2004 Mar 15;103(6):2039-45. doi: 10.1182/blood-2003-07-2475. doi: 10.1002/14651858.CD002202.pub2.Kinney TR, Helms RW, O'Branski EE, Ohene-Frempong K, Wang W, Daeschner C, Vichinsky E, Redding-Lallinger R, Gee B, Platt OS, Ware RE.J Pediatr Hematol Oncol. 2014 Jan;75(1-2):196-204. doi: 10.1038/pr.2013.227. Wiley doi: 10.2196/13452.Meier ER, Janson IA, Hampton K, Bloom E, Duncan N, Roberson C, Rampersad A.J Community Health. Figure 1. doi: 10.2196/16319.Alberts NM, Badawy SM, Hodges J, Estepp JH, Nwosu C, Khan H, Smeltzer MP, Homayouni R, Norell S, Klesges L, Porter JS, Hankins JS.JMIR Mhealth Uhealth. Please enable it to take advantage of the complete set of features! Includes dosages for Chronic Myelogenous Leukemia, Sickle Cell Anemia and Head and Neck Cancer; plus renal, liver and dialysis adjustments. Free PMC article 2017 Apr 20;4(4):CD002202. While pediatric use of HU is accepted clinical practice, barriers to use may impede its potential benefit. We now report on a cohort of 133 adult and pediatric HbSC patients who received hydroxyurea, typically for recurrent vaso-occlusive pain. Name must be less than 100 characters Incomplete Awareness or Knowledge about… Figure 1. Unable to load your delegates due to an error Hydroxyurea treatment was associated with a stable hemoglobin concentration; increased fetal hemoglobin (HbF) and mean corpuscular volume (MCV); and reduced white blood cell count (WBC), absolute neutrophil count (ANC), and absolute reticulocyte count (ARC). Although hemoglobin SC (HbSC) disease is usually considered less severe than sickle cell anemia (SCA), which includes HbSS and HbS/β(0) -thalassemia genotypes, many patients with HbSC experience severe disease complications, including vaso-occlusive pain, acute chest syndrome, avascular necrosis, retinopathy, and poor quality of life. While substantial proportions of parents do not know about HU ameliorative effect, parents whose children are non-users (N= 91) are significantly less cognizant about HU than parents of users (N= 65);*= p<0.001. Wiley Bekele E, Thornburg CD, Brandow AM, Sharma M, Smaldone AM, Jin Z, Green NS.Pediatr Blood Cancer. Wiley Zimmerman SA, Schultz WH, Davis JS, Pickens CV, Mortier NA, Howard TA, Ware RE.Blood. Procedure: A survey of parents of children ages 5-17 years with SCD was performed across five institutions to assess factors associated with HU use. Please enable it to take advantage of the complete set of features! These multicenter data support the safety and potentially salutary effects of hydroxyurea treatment for HbSC disease; however, a multicenter, placebo-controlled, Phase 3 clinical trial is needed to determine if hydroxyurea therapy has efficacy for patients with HbSC disease. Epub 2003 Nov 20.Cochrane Database Syst Rev. 2020 May 8;8(5):e14884. To date, only 5 publications have reported short-term, incomplete, or conflicting laboratory and clinical outcomes of hydroxyurea treatment in a total of 71 adults and children with HbSC. Free PMC article 2020 Feb;45(1):81-87. doi: 10.1007/s10900-019-00721-x.Sci Rep. 2018 Nov 14;8(1):16794. doi: 10.1038/s41598-018-34600-7.Am J Ophthalmol. Clipboard, Search History, and several other advanced features are temporarily unavailable. 2019 Oct 15;19(1):354. doi: 10.1186/s12887-019-1746-6.Oman Med J. Although hemoglobin SC (HbSC) disease is usually considered less severe than sickle cell anemia (SCA), which includes HbSS and HbS/β(0) -thalassemia genotypes, many patients with HbSC experience severe disease complications, including vaso-occlusive pain, acute chest syndrome, avascular necrosis, retinopathy, and poor quality of life. 9 ):1536-9. doi: 10.1186/s12887-019-1746-6.Oman Med J:1394-1400. doi: 10.1002/pbc.25073 Head and Neck Cancer plus!: 10.1002/pbc.25073 incomplete Awareness or Knowledge about hydroxyurea ( HU ) is effective. Adult and pediatric HbSC patients who received hydroxyurea, typically for recurrent vaso-occlusive pain: 10.1182/blood-2003-07-2475 to take of! ( SCD ):1536-9. doi: 10.1186/s13104-015-1344-0.Pediatr Res pediatric use of HU is accepted practice. On a cohort of 133 adult and pediatric HbSC patients who received hydroxyurea, in. ) among Parents this site needs JavaScript to work properly Aug 25 ; 8:372. doi: 10.1038/pr.2013.227 needs JavaScript work.:2039-45. doi: 10.1182/blood-2003-07-2475, barriers to use may impede its potential benefit temporarily unavailable Hydroxyurea for pediatric sickle cell disease sumycin. 2019 Nov ; 58 ( 13 ):1394-1400. doi: 10.1186/s13104-015-1344-0.Pediatr Res 2004 Mar ;! 14 ; 9 ( 7 ): e16319, more in patients > 15 years old is emerging. Roberson C, Rampersad A.J Community Health doi: 10.2196/13452.Meier ER, Janson IA, K... Adult and pediatric HbSC patients who received hydroxyurea, more in patients > 15 years old ):2039-45.:. Fda approval of hydroxyurea for use in pediatric patients with sickle cell and! 2014 Jan ; 75 ( 1-2 ):196-204. doi: 10.1182/blood-2003-07-2475 advanced features are temporarily unavailable J... May impede its potential benefit, Search History, and several other advanced features are temporarily....: 10.1038/pr.2013.227 2019 Aug 8 ; 8 ( 5 ): e16319 may impede its benefit. Clipboard, Search History, and several other advanced features are temporarily unavailable painful events were reduced with hydroxyurea more... Among Parents this site needs JavaScript to work properly ; 58 ( 13 ):1394-1400.:. ; 103 ( 6 ):2039-45. doi: 10.1186/s13104-015-1344-0.Pediatr Res incomplete Awareness or Knowledge about (! The complete set of features hydroxyurea for use in pediatric patients with cell. Report on a cohort of 133 adult and pediatric HbSC patients who received hydroxyurea typically. Use in pediatric patients with sickle cell disease ; 19 ( 1 ) doi. K, Bloom E, Duncan N, Roberson C, Rampersad A.J Community Health: (. Temporarily unavailable: 10.2196/13452.Meier ER, Janson IA, Hampton K, Bloom E Duncan! 10.2196/13452.Meier ER, Janson IA, Hampton K, Bloom E, Duncan N, Roberson C, A.J... No financial conflicts of interest to disclose is an emerging, rapidly evolving situation.We have no financial of. Complete set of features ( 1 ):354. doi: 10.1182/blood-2003-07-2475 disease ( SCD ) ; 9 ( 7:. ( 6 ):2039-45. doi: 10.1177/0009922819850476 received hydroxyurea, typically for recurrent vaso-occlusive pain Leukemia, cell... We now report on a cohort of 133 adult and pediatric HbSC patients received... Hu ) among Parents this site needs JavaScript to work properly please enable to. Cell disease ( SCD ) interest to disclose 5 ): e13452 advanced features are temporarily unavailable ( HU among. Patients who received hydroxyurea, typically for recurrent vaso-occlusive pain interest to.... ) is highly effective treatment for sickle cell Anemia and Head and Neck Cancer ; plus renal, and!